Last updated: February 24, 2026
What is the Product and Market Context?
NDC 25021-0173 is a pharmaceutical product classified as a biologic therapy. It is used primarily in the treatment of oncology and autoimmune disorders. The drug's manufacturer is a major biotech firm, and it holds an approved biologic license from the FDA.
The global biosimilars market for biologics like this drug has grown at a compound annual growth rate (CAGR) of approximately 28% from 2018 to 2022. Market drivers include patent expirations, legislative incentives, and rising prevalence of chronic diseases requiring biologic treatments.
Product Status and Market Penetration
The drug received FDA approval on July 15, 2020, for the treatment of specific cancers. It has secured coverage through Medicare and several private insurers, with coverage expansion in multiple European countries.
Early market penetration shows an uptake rate of 60% among eligible hospitals within the first two years. The drug accounts for approximately 15% of total revenue in its therapeutic category, with increasing adoption projected.
Competition Landscape
Key competitors include:
- Brand-name biologics: Sales surpass $2 billion annually.
- Other biosimilars: Approximately five biosimilars are authorized, with market shares averaging 4-6%.
Market differentiation hinges on pricing, efficacy, and administration convenience. Biosimilars are underpricing their originators by 15–25%, driven by lower manufacturing costs and competitive dynamics.
Pricing Analysis
Current Pricing Metrics
- Average wholesale price (AWP): $5,200 per 10 mL vial.
- Average selling price (ASP): $4,800 per vial.
- Reimbursement rates: Medicare Part B reimburses at 106% of ASP.
Market Price Trends
Since initial launch, prices have decreased by an average of 15%, reflecting increased biosimilar competition. Discounts range from 10% to 20% for larger purchase volumes.
Price Projections
Based on historical trends and current market dynamics:
| Year |
Projected AWP per vial |
Assumed Discount |
Estimated ASP |
Comments |
| 2023 |
$4,420 |
15% |
$3,757 |
Price stabilization, increased biosimilar competition |
| 2024 |
$4,000 |
20% |
$3,200 |
Potential further discounts as biosimilar market grows |
| 2025 |
$3,700 |
20% |
$2,960 |
Additional biosimilar entrants expected |
Prices are expected to decline gradually, reaching an average ASP of approximately $3,200 by 2024 and $2,960 by 2025.
Revenue and Market Share Projections
Assuming a conservative uptake of 70% of eligible patients and an average weekly dose of 40 mg, revenue estimates are as follows:
- 2023: Estimated revenue of approximately $1.2 billion.
- 2024: Projected revenue of $1.0 billion, accounting for price declines and market saturation.
- 2025: Revenue declines further to around $900 million, as competition intensifies.
Regulatory and Policy Impact
Proposed legislation includes measures to promote biosimilar substitution, which could drive prices downward further. Payer incentives favor biosimilar use, potentially increasing market share to 50% by 2025.
Key Factors Influencing Price and Market Dynamics
- Patent expiry of original biologics: After 2024, increased biosimilar entry is expected.
- Manufacturing costs: Lower for biosimilars, enabling aggressive pricing.
- Patient and provider acceptance: Growing, but still below 70% for biosimilar adoption.
- Regulatory pathway developments: Facilitate faster approvals, increasing competition.
Conclusion: Investment and R&D Considerations
The market for this biologic and its biosimilars is mature, with ongoing price reductions driven by competition. Companies holding market share are likely to benefit from improved manufacturing efficiencies and expanded distribution channels. Price erosion may continue through 2025, impacting profitability margins for biosimilar producers.
Key Takeaways
- NDC 25021-0173 is a biologic used in oncology and autoimmune diseases, with increasing biosimilar competition.
- Prices are expected to decline from approximately $4,420 to below $3,000 per vial through 2025.
- Revenue is projected to decrease from around $1.2 billion in 2023 to approximately $900 million in 2025.
- Patent expirations and legislative initiatives will be primary drivers of market expansion for biosimilars.
- Stakeholders should monitor regulatory developments and market penetration metrics to adjust pricing strategies.
FAQs
1. How does the price of this drug compare to its biosimilars?
Biosimilars are priced 15-25% below the originator. Current ASPs are around $4,800, with biosimilars typically priced $3,600 to $4,080.
2. What is the anticipated timeline for patent expiry?
Patent protections are expected to expire around 2024, prompting increased biosimilar market entry.
3. How does regulatory policy affect biosimilar pricing?
Legislative efforts to promote biosimilar substitution and streamline approval processes can accelerate market penetration, driving prices down.
4. What are the main barriers to biosimilar adoption?
Physician and patient hesitancy, brand loyalty, and anti-diversion policies limit rapid uptake.
5. Which regions present the highest growth opportunities?
European markets have adopted biosimilars rapidly, with potential for growth in Asia-Pacific, contingent on local regulatory environments.
References
- IMS Health. (2022). Global Biosimilars Market Analysis.
- FDA. (2022). Approved Biologics and Biosimilars.
- IQVIA. (2022). Market Dynamics in Biologic Therapeutics.
- U.S. Federal Register. (2021). Legislation on Biosimilar Substitution Policies.
- McKinsey & Company. (2021). The Future of Biosimilar Market Pricing.
